KALVISTA PHARMACEUTICALS, INC.
55 Cambridge Parkway
Suite 901E
Cambridge, Massachusetts 02142
July 17, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: | Tamika Sheppard |
Re: | KalVista Pharmaceuticals, Inc. |
Registration Statement on Form S-3 |
Filed July 11, 2024 |
File No. 333-280759 |
Requested Date: July 19, 2024
Requested Time: 4:30 PM Eastern Time
Ladies and Gentlemen:
KalVista Pharmaceuticals, Inc. (the Registrant) hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the Requested Date and Requested Time set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission.
The Registrant hereby authorizes Julia Forbess or Robert A. Freedman, both of whom are attorneys with the Registrants outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Forbess at (415) 875-2420 or, in her absence, to Mr. Freedman at (206) 389-4524.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Sincerely, | ||
KALVISTA PHARMACEUTICALS, INC. | ||
By: | /s/ Benjamin L. Palleiko | |
Benjamin L. Palleiko | ||
Chief Executive Officer |
cc: | Robert A. Freedman, Esq. | |
Julia Forbess, Esq. | ||
Fenwick & West LLP |